酶介导的纳米反应器具有级联代谢调制,用于增强化学-化学动力学联合治疗
Qiaoli Feng1, Danmiao Zheng2, Zhonghui Ma2
1Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Journal of colloid and interface science
|September 9, 2025
概括
这项研究开发了一种纳米反应器,通过结合化疗和化学动力学疗法来治疗癌症. 它针对瘤中的乳酸,产生反应性氧物种,以加强癌细胞的破坏.
科学领域:
- 在瘤学瘤学.
- 纳米医学是一种纳米医学.
- 生物化学 生物化学
背景情况:
- 瘤微环境 (TME) 的异质性挑战了单剂癌症疗法.
- 乳酸 (LA) 在TME中的积累提供了代谢操纵的目标.
- 开发能够解决TME复杂性的组合疗法至关重要.
研究的目的:
- 为了创建一个纳米反应器,用于联合化疗和化学动力学疗法 (CDT).
- 为了利用乳酸代谢来改善癌症治疗.
- 为了改善瘤向和治疗疗效.
主要方法:
- 带有--铁纳米颗粒 (ZCMF NPs),乳酸氧化酶 (LOX) 和多克索鲁比 (DOX) 的非对称的半孔性化纳米颗粒 (AMS NPs).
- 纳入内部化RGD (iRGD) 进行增强瘤向.
- 一个纳米反应器 (AMS@ZCMF-LOX-DOX-iRGD NP) 的形成,用于联合化疗-CDT.
主要成果:
- 纳米反应器释放金属离子,触发芬顿类反应并产生细胞毒性基 (OH).
- 洛克斯将乳酸转化为H2O2,维持CDT.
- 联合化疗-CDT和代谢重编程显示出协同作用的抗瘤效应.
结论:
- 纳米反应器通过向瘤乳酸代谢,有效地结合化疗和CDT.
- 这种方法为协同瘤根除提供了一种战略.
- 这些发现为开发有针对性,可调节的组合癌症疗法提供了洞察力.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Electron Transport Chain: Complex I and II
18.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.5K


